Preclinical and clinical implications of TERT promoter mutation in glioblastoma multiforme

Jeong,Da Eun; Woo,Seon Rang; Nam,Hyun; Nam,Do‑Hyun; Lee,Jae‑Ho; Joo,Kyeung Min

doi:10.3892/ol.2017.7196

Preclinical and clinical implications of TERT promoter mutation in glioblastoma multiforme

Authors:
- Da Eun Jeong
- Seon Rang Woo
- Hyun Nam
- Do‑Hyun Nam
- Jae‑Ho Lee
- Kyeung Min Joo
View Affiliations

Affiliations: Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul 06531, Republic of Korea, Department of Anatomy and Cell Biology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06531, Republic of Korea, Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06531, Republic of Korea, Department of Anatomy, Keimyung University School of Medicine, Daegu 42601, Republic of Korea
Published online on: October 16, 2017 https://doi.org/10.3892/ol.2017.7196
Pages: 8213-8219

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The promoter region of the telomerase reverse transcriptase gene (TERT) is mutated in a subpopulation of patients with glioblastoma multiforme (GBM). In the present study, preclinical and clinical implications of the mutation were analyzed in 25 GBMs to evaluate its utility as a therapeutic target. Associations between the TERT promoter mutation and a number of preclinical/clinical characteristics were analyzed. Notably, the TERT promoter mutation was identified in 92.3% of GBMs where dissociated cells revealed in vitro sphere formation capacity; while the TERT promoter mutation was identified in 33.3% of GBMs without in vitro sphere formation capacity (P=0.004). In addition, this significantly increased mutation rate was observed in GBMs with in vivo tumorigenic potential (80% vs. 0%; P=0.004). Furthermore, patients with GBM exhibiting the TERT promoter mutation demonstrated significantly decreased overall survival rate compared with patients lacking this mutation (81.7 vs. 152.6 weeks; P=0.026). The results of the present study indicated that the TERT promoter mutation is associated with the self‑renewal capacity of GBM cells and clinical aggressiveness of GBMs, which may be translated to a targeting therapy against TERT to inhibit the self‑renewal of GBM cells.

View Figures

View References

1	Mosrati MA, Malmström A, Lysiak M, Krysztofiak A, Hallbeck M, Milos P, Hallbeck AL, Bratthäll C, Strandéus M, Stenmark-Askmalm M and Söderkvist P: TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma. Oncotarget. 6:16663–16673. 2015. View Article : Google Scholar : PubMed/NCBI
2	Reitman ZJ, Pirozzi CJ and Yan H: Promoting a new brain tumor mutation: TERT promoter mutations in CNS tumors. Acta Neuropathol. 126:789–792. 2013. View Article : Google Scholar : PubMed/NCBI
3	Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 17:98–110. 2010. View Article : Google Scholar : PubMed/NCBI
4	Labussière M, Boisselier B, Mokhtari K, Di Stefano AL, Rahimian A, Rossetto M, Ciccarino P, Saulnier O, Paterra R, Marie Y, et al: Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes. Neurology. 83:1200–1206. 2014. View Article : Google Scholar : PubMed/NCBI
5	Nonoguchi N, Ohta T, Oh JE, Kim YH, Kleihues P and Ohgaki H: TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol. 126:931–937. 2013. View Article : Google Scholar : PubMed/NCBI
6	Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL, Giovanella BC, et al: TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA. 110:pp. 6021–6026. 2013, View Article : Google Scholar : PubMed/NCBI
7	George J, Banik NL and Ray SK: Knockdown of hTERT and concurrent treatment with interferon-gamma inhibited proliferation and invasion of human glioblastoma cell lines. Int J Biochem Cell Biol. 42:1164–1173. 2010. View Article : Google Scholar : PubMed/NCBI
8	Beck S, Jin X, Sohn YW, Kim JK, Kim SH, Yin J, Pian X, Kim SC, Nam DH, Choi YJ and Kim H: Telomerase activity-independent function of TERT allows glioma cells to attain cancer stem cell characteristics by inducing EGFR expression. Mol Cells. 31:9–15. 2011. View Article : Google Scholar : PubMed/NCBI
9	Joo KM, Kim J, Jin J, Kim M, Seol HJ, Muradov J, Yang H, Choi YL, Park WY, Kong DS, et al: Patient-specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ. Cell Rep. 3:260–273. 2013. View Article : Google Scholar : PubMed/NCBI
10	Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
11	Joo KM, Kim SY, Jin X, Song SY, Kong DS, Lee JI, Jeon JW, Kim MH, Kang BG, Jung Y, et al: Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab Invest. 88:808–815. 2008. View Article : Google Scholar : PubMed/NCBI
12	Pollard SM, Yoshikawa K, Clarke ID, Danovi D, Stricker S, Russell R, Bayani J, Head R, Lee M, Bernstein M, et al: Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell. 4:568–580. 2009. View Article : Google Scholar : PubMed/NCBI
13	Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, Ueyama Y, Koyanagi Y, Sugamura K, Tsuji K, et al: NOD/SCID/gamma(c)(null) mouse: An excellent recipient mouse model for engraftment of human cells. Blood. 100:3175–3182. 2002. View Article : Google Scholar : PubMed/NCBI
14	Liu T, Wang N, Cao J, Sofiadis A, Dinets A, Zedenius J, Larsson C and Xu D: The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene. 33:4978–4984. 2014. View Article : Google Scholar : PubMed/NCBI
15	Oh YT, Cho HJ, Kim J, Lee JH, Rho K, Seo YJ, Choi YS, Jung HJ, Song HS, Kong DS, et al: Translational validation of personalized treatment strategy based on genetic characteristics of glioblastoma. PLoS One. 9:e1033272014. View Article : Google Scholar : PubMed/NCBI
16	Olshen AB, Venkatraman ES, Lucito R and Wigler M: Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics. 5:557–572. 2004. View Article : Google Scholar : PubMed/NCBI
17	Li H and Durbin R: Fast and accurate short read alignment with Burrow-Wheeler transform. Bioinformatics. 25:1754–1760. 2009. View Article : Google Scholar : PubMed/NCBI
18	Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G and Durbin R: 1000 Genome Project Data Processing Subgroup: The sequence Alignment/Map format and SAMtools. Bioinformatics. 25:2078–2079. 2009. View Article : Google Scholar : PubMed/NCBI
19	Wu TD and Nacu S: Fast and SNP-tolerant detection of complex variants and splicing in short reads. Bioinformatics. 26:873–881. 2010. View Article : Google Scholar : PubMed/NCBI
20	Vinagre J, Pinto V, Celestino R, Reis M, Pópulo H, Boaventura P, Melo M, Catarino T, Lima J, Lopes JM, et al: Telomerase promoter mutations in cancer: An emerging molecular biomarker? Virchows Arch. 465:119–133. 2014. View Article : Google Scholar : PubMed/NCBI
21	Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A, Becker M and Merk J: Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res. 14:6456–6468. 2008. View Article : Google Scholar : PubMed/NCBI
22	John T, Kohler D, Pintilie M, Yanagawa N, Pham NA, Li M, Panchal D, Hui F, Meng F, Shepherd FA and Tsao MS: The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer. Clin Cancer Res. 17:134–141. 2011. View Article : Google Scholar : PubMed/NCBI
23	Lee HW, Lee JI, Lee SJ, Cho HJ, Song HJ, Jeong DE, Seo YJ, Shin S, Joung JG, Kwon YJ, et al: Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy. Clin Cancer Res. 21:1172–1182. 2015. View Article : Google Scholar : PubMed/NCBI
24	Hale JS, Otvos B, Sinyuk M, Alvarado AG, Hitomi M, Stoltz K, Wu Q, Flavahan W, Levison B, Johansen ML, et al: Cancer stem cell-specific scavenger receptor CD36 drives glioblastoma progression. Stem Cells. 32:1746–1758. 2014. View Article : Google Scholar : PubMed/NCBI
25	Borah A, Raveendran S, Rochani A, Maekawa T and Kumar DS: Targeting self-renewal pathways in cancer stem cells: Clinical implications for cancer therapy. Oncogenesis. 4:e1772015. View Article : Google Scholar : PubMed/NCBI
26	Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, et al: TERT promoter mutations in familial and sporadic melanoma. Science. 339:959–961. 2013. View Article : Google Scholar : PubMed/NCBI
27	Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L and Garraway LA: Highly recurrent TERT promoter mutations in human melanoma. Science. 339:957–959. 2013. View Article : Google Scholar : PubMed/NCBI
28	Chiba K, Johnson JZ, Vogan JM, Wagner T, Boyle JM and Hockemeyer D: Cancer-associated TERT promoter mutations abrogate telomerase silencing. Elife. 4:2015. View Article : Google Scholar
29	Ko E, Seo HW, Jung ES, Kim BH and Jung G: The TERT promoter SNP rs2853669 decreases E2F1 transcription factor binding and increases mortality and recurrence risks in liver cancer. Oncotarget. 7:684–699. 2016. View Article : Google Scholar : PubMed/NCBI
30	Huse JT: TERT promoter mutation designates biologically aggressive primary glioblastoma. Neuro Oncol. 17:5–6. 2015. View Article : Google Scholar : PubMed/NCBI
31	Simon M, Hosen I, Gousias K, Rachakonda S, Heidenreich B, Gessi M, Schramm J, Hemminki K, Waha A and Kumar R: TERT promoter mutations: A novel independent prognostic factor in primary glioblastomas. Neuro Oncol. 17:45–52. 2015. View Article : Google Scholar : PubMed/NCBI
32	Spiegl-Kreinecker S, Lötsch D, Ghanim B, Pirker C, Mohr T, Laaber M, Weis S, Olschowski A, Webersinke G, Pichler J and Berger W: Prognostic quality of activating TERT promoter mutations in glioblastoma: Interaction with the rs2853669 polymorphism and patient age at diagnosis. Neuro Oncol. 17:1231–1240. 2015. View Article : Google Scholar : PubMed/NCBI